EP4185312A1 - Bombax costatum blütenextrakt mit hohem polysaccharidgehalt - Google Patents

Bombax costatum blütenextrakt mit hohem polysaccharidgehalt

Info

Publication number
EP4185312A1
EP4185312A1 EP21755806.3A EP21755806A EP4185312A1 EP 4185312 A1 EP4185312 A1 EP 4185312A1 EP 21755806 A EP21755806 A EP 21755806A EP 4185312 A1 EP4185312 A1 EP 4185312A1
Authority
EP
European Patent Office
Prior art keywords
extract
skin
polysaccharides
disorders
advantageously
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21755806.3A
Other languages
English (en)
French (fr)
Inventor
Sophie LECLERE- BIENFAIT
Stéphanie BREDIF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Expanscience SA
Original Assignee
Laboratoires Expanscience SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Expanscience SA filed Critical Laboratoires Expanscience SA
Publication of EP4185312A1 publication Critical patent/EP4185312A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to an extract of Bombax costatum flowers, said extract being rich in polysaccharides.
  • the invention also relates to a cosmetic, pharmaceutical or dermatological composition comprising such an extract.
  • the invention also relates to a method for extracting an extract of Bombax costatum flowers rich in polysaccharides, as well as the extract that can be obtained by said method.
  • the invention also relates to such a composition or such an extract for its use in the prevention or treatment of disorders or pathologies of the skin, mucous membranes or appendages, and in the prevention or treatment of vascular disorders.
  • the invention finally relates to a cosmetic care process for the skin, appendages or mucous membranes, with a view to improving their condition or their appearance, consisting in administering such a composition or such an extract.
  • the Bombax costatum belongs to the bombacaceae family (APG: Malvaceae).
  • the Bombax costatum is also called Bombax andrieui or Bombax houardii.
  • the Bombax costatum is more commonly called Kapok tree with red flowers, cheese tree, red kapok tree, false kapok tree, forest kapok tree, Voaka (in the Moré language), or Boumbou (in the Jula language).
  • Bombax is a pantropical genus comprising 8 species: 2 in Africa, 5 in Asia, and 1 in Oceania, present as far as the Solomon Islands. In the past, the delimitation of the genus Bombax was much wider. Bombax costatum is sometimes considered conspecific with Bombax buonopozense.
  • Bombax costatum is a fairly common food tree: the leaves are dried and eaten like those of the Baobab; the flowers, especially the calyxes, are also eaten.
  • Burkina Faso the bark is used to stain teeth red.
  • the flowers are commonly harvested for the fleshy calyx which is cooked and eaten as a vegetable.
  • the leaves are also eaten as a vegetable.
  • the immature fruits and sometimes the flowers are added as thickeners in sauces. Young immature fruits are also used in the preparation of a drink.
  • the seed oil is edible.
  • the flowers are highly valued as bees.
  • Maceration of the powdered root is eaten in sauce or applied as a bath against epilepsy. Bark preparations are applied to wounds to promote healing.
  • the bark is also used to prepare a medicine against trichomoniasis, amoebiasis and other forms of dysentery.
  • a bath in a stem bark extract is taken against insanity.
  • Powdered stem bark is used as a fumigant against headache.
  • a bark compress can be placed on the head.
  • the leaves are prescribed with other medicinal plants to treat leucorrhoea and diarrhoea.
  • An extract of crushed leaves is taken as a drink against problems during childbirth.
  • a bath in an extract of crushed leaves is taken repeatedly against convulsions.
  • a tea of dried leaves is taken or applied to the body against measles.
  • a decoction of leaves and stem or root bark is taken as a drink in cases of severe swelling.
  • a decoction of leaves and young twigs is drunk to treat jaundice.
  • a leaf decoction is also given to children to drink against rickets.
  • Different parts of the plant are used to promote lactation and as a tonic against fatigue. The skin is rubbed with leaves mixed with shea butter against leprosy.
  • a decoction of the bark and leaves and parts of other plants is taken against menstruation disorders.
  • the leaves are emollient and a warm bath in a leaf decoction may be prescribed for patients with fever, especially children.
  • the leaves are also used in hookworm treatments and the flowers in tapeworm treatments.
  • Polyosides or polysaccharides or glycans are arbitrarily defined as high molecular weight polymers resulting from the condensation of a large number of oses or sugars. They participate in different aspects in the life and even survival of plants. For example, they are responsible for the rigidity of the cell walls of higher plants (celluloses, hemi-cellulose, lignins, etc.), they are forms of energy storage (starch) and can protect tissues against dehydration because of their hydrophilic power ...
  • the skin microbiota is all the microorganisms (bacteria, viruses, fungi, etc.) residing on and in the skin.
  • the microbiota is present even in the dermis and adipose tissue and eccrine glands (Nakatsuji et al 2013).
  • the microbiota should not be confused with the microbiome which is the set of genes (genome of bacteria).
  • flora There are 2 major types of flora: - resident flora composed of commensal germs living at the expense of their host without causing damage; and
  • transient flora composed of saprophytic germs (harmless) and opportunistic pathogens.
  • the skin represents an environmental niche, a reservoir of nutrients for certain bacteria.
  • Bacteria can stimulate immune defenses; and the skin in response can develop a veritable anti-microbial shield that inhibits the growth of pathogens and stimulates the production of anti-microbial molecules, which contributes to maintaining a good state of skin health.
  • the same bacterium can be symbiotic or pathobiontic.
  • Symbionts lead to physiological inflammation, barrier protection, surveillance/tolerance (PAMs) by the skin and its innate immunity, absence of virulence, and sequestration of TLRs (Toll-like receptors).
  • Symbionts live in biofilms. It sometimes occurs for various intrinsic and/or environmental reasons, a loss of control of these symbionts which then become pathobionts.
  • the virulence factors of the microbiota increase, as well as inflammatory phenomena and the activation of the immune system. Commensal bacteria are sometimes eradicated.
  • atopic dermatitis Under so-called normal skin conditions, the host's immunity maintains the balance of the microbiota.
  • a deficiency in the immune system leads to dysbiosis and specific skin pathologies: atopic dermatitis, acne, psoriasis.
  • the Applicant has discovered that the extracts of Bombax costatum flowers, preferably of Bombax costatum calyxes, have cosmetic and dermatological properties never before described.
  • the subject of the invention is an extract rich in polysaccharides from flowers of Bombax costatum, preferably from calyxes of Bombax costatum.
  • the flower is the part of the plant comprising, from the outside to the inside, when complete:
  • the term "flower” includes at least the corolla and the calyx.
  • the flower can also be complete, that is to say include the calyx, the corolla, the androecium, and the gynoecium or pistil.
  • the extract according to the invention is preferably an extract of calyces of Bombax costatum.
  • extract rich in polysaccharides is meant an extract comprising mainly or essentially polysaccharides, that is to say that the majority compounds are polysaccharides.
  • the extract according to the invention thus advantageously comprises at least 15% by weight of polysaccharides, more advantageously at least 20% by weight, preferably at least 30% by weight, more advantageously at least 50% by weight, relative to the weight total dry extract.
  • the extract according to the invention thus advantageously comprises from 15% to 65% by weight of polysaccharides, more advantageously from 20% to 65% by weight, of preferably from 30% to 65% by weight, more advantageously from 50% to 65% by weight, relative to the total weight of the dry extract.
  • the percentages are expressed relative to the total weight of said dry extract (before any addition of a drying medium) and the assay is carried out according to the sulfuric phenol method (Dubois method) or according to the anthrone method - spectro assay - colorimetric of total sugars.
  • the polysaccharides present in the extract have an apparent molecular mass of between 1500 kDa and 6000 kDa, advantageously between 3000 kDa and 6000 kDa (determination by Gas Phase Chromatography).
  • the polysaccharides of the extract according to the invention comprise monosaccharides and derivatives chosen from the group consisting of galactose, rhamnose, galacturonic acid, glucuronic acid, and mixtures thereof.
  • galactose is meant D-galactose and L-galactose.
  • rhamnose is understood to mean D-rhamnose and L-rhamnose.
  • the polysaccharides of the extract according to the invention comprise a mixture of galactose, rhamnose, galacturonic acid, and glucuronic acid.
  • the polysaccharides of the extract according to the invention comprise (% by weight relative to the total weight of all the sugars (monosaccharides) present):
  • the extract according to the invention is advantageously substantially free of polyphenols.
  • the extract according to the present invention comprises less than 1% by weight of polyphenols, advantageously less than 0.5% by weight of polyphenols, relative to the total weight of the dry extract.
  • the extract rich in polysaccharides described above is advantageously obtained by solid/liquid extraction of the flowers, preferably of the calyces, of Bombax costatum, in water.
  • the polysaccharides can then be purified and/or re-solubilized in a suitable solvent in order to guarantee their physical and microbiological stability or dried by methods known to those skilled in the art.
  • the invention also relates to a method for preparing an extract rich in polysaccharides from flowers, preferably calyxes, of Bombax costatum, comprising at least one step of solid/liquid extraction in water and under optimal conditions. pH, time and temperature, known to those skilled in the art.
  • the method for preparing an extract rich in polysaccharides from flowers comprises the following successive steps: a) grinding the flowers, in particular the calyxes, of Bombax costatum; b) extraction of the flowers, in particular the calyxes, ground in water under optimal conditions of duration, pH and temperature; c) separation of the solid phase and the liquid phase by decantation, and/or centrifugation and/or precipitation and/or successive filtrations; and d) optionally, step of decolorizing the liquid phase using a suitable adjuvant; e) optionally, drying the extract obtained in step c) or d); and f) optionally, stabilization of the polysaccharides in a liquid medium in a solvent suitable for preserving the physico-chemical properties of the extract and for controlling microbial growth.
  • the process for preparing an extract rich in polysaccharides from flowers, preferably calyxes, of Bombax costatum comprises the following successive steps: a) grinding the flowers, in particular the calyxes, of Bombax costatum; b) extraction of the flowers, in particular the calyxes, crushed in water; c) separation of the solid phase and the liquid phase by decantation, and/or centrifugation and/or precipitation and/or successive filtrations; d) optionally, step of decolorization of the liquid phase using a suitable adjuvant; e) optionally, drying the extract obtained in step c) or d); and f) optionally, physical and microbiological stabilization of the extract obtained in step c), d) or e).
  • Step a) of grinding the plant can be carried out by methods known to those skilled in the art, in particular using a knife mill or a hammer mill.
  • Step b) of extraction is preferably carried out in the presence of water.
  • the percentage of crushed plant introduced into the water is advantageously between 2% and 10% w/w and preferably between 2% and 5% w/w, more advantageously 2% w/w.
  • This solid/liquid extraction is preferably carried out at a temperature comprised between 20°C and 100°C, in particular between 50°C and 90°C, more particularly between 70°C and 90°C, typically 90°C.
  • the extraction time is advantageously between 30 minutes and 4 hours, in particular between 1 hour and 3 hours, advantageously it is approximately 1 hour.
  • Step c) of separating the solid phase and the liquid phase is carried out by methods known to those skilled in the art, in particular by decantation, centrifugation and/or successive filtrations and/or purification by precipitation of the polysaccharides with using a suitable solvent and preferably ethanol or a saline solution.
  • the liquid phase obtained is advantageously purified and concentrated, for example by ultrafiltration and/or sterilizing filtration.
  • Step c) is carried out until a liquid phase is obtained which has perfect clarity and microbiological cleanliness of a degree less than or equal to 100 CFU/g in total germ.
  • step d) of bleaching the liquid phase is carried out, this is done by methods known to those skilled in the art, in particular by adding an adjuvant such as activated carbon or suitable and known bleaching earths. of the skilled person.
  • the extraction with water leads to an extract very poor in polyphenols or substantially devoid of polyphenols (polyphenols typically at trace state).
  • the extract according to the invention preferably obtained by solid/liquid extraction in water, typically has a content of less than 1% by weight, preferably less than 0.5% by weight, relative to the total weight of the dry extract.
  • the method according to the invention comprises at least one step of specific filtration and/or purification (step c)) and/or decolorization on activated carbon (step d)) which makes it possible to eliminate the remaining polyphenols if necessary.
  • the method comprises at least one purification step such as ultrafiltration which makes it possible to separate the “small” molecules such as the polyphenols from the “large” molecules (size greater than 1 million Daltons) such as the polysaccharides.
  • the treatment with activated carbon during step d) of discoloration also contributes to lowering the level of polyphenols of the extract to be advantageously present only in trace amounts at the end of the process according to the present invention.
  • the extract rich in polysaccharides according to the invention can be stabilized by a drying step e), by methods known to those skilled in the art.
  • Step e) of drying can, for example, be carried out in the presence of a support of the maltodextrin or acacia fiber type (Fibregum® company CNI).
  • the carrier content typically varies according to a ratio ranging from 0% to 80% carrier relative to the percentage of dry matter obtained in the liquid form of the extract.
  • the extract is preferably dried by freeze-drying or atomization in order to obtain a final powder.
  • Stage f) of physical and microbiological stabilization of the product obtained in stage c), d) or e) is advantageously carried out by partial elimination of the water and replacement with a solvent advantageously chosen from vegetable glycerin, glycols, and mixtures thereof, in particular from vegetable glycerin, glycols of vegetable origin and mixtures thereof, more particularly from a propanediol or propylene glycol, in particular 1,3-propanediol, and vegetable glycerin.
  • a solvent advantageously chosen from vegetable glycerin, glycols, and mixtures thereof, in particular from vegetable glycerin, glycols of vegetable origin and mixtures thereof, more particularly from a propanediol or propylene glycol, in particular 1,3-propanediol, and vegetable glycerin.
  • step f) is carried out in the liquid phase by reducing the amount of water by evaporation to less than 50% by weight and preferably less than 20% by weight, relative to the total mass of the extract and substitution with a bacteriostatic or bactericidal solvent chosen from vegetable glycerin, glycols, and mixtures thereof, in particular from vegetable glycerin, glycols of plant origin and mixtures thereof, more particularly from a propanediol or propylene glycol, in particular 1,3-propanediol, and vegetable glycerin.
  • the water/solvent ratio will then be advantageously between the ratios 50/50 and 0/100 (w/w) and preferably between 30/70 (w/w) and 10/90 (w/w) and advantageously
  • the extract rich in polysaccharides according to the invention can be obtained according to the following process: a′) Dissolving the ground flower at 2% (w/w) in water b′ ) Extraction with stirring for 1 h at 90° C.; c’) Purification by stages of successive filtrations; d’) Sterile filtration; and e′) Stabilization of the extract obtained by evaporation of water and addition of glycerin to obtain a water/glycerin ratio of between 50/50 and 0/100, advantageously between 30/70 and 10/90.
  • extract according to the invention designate the extract as such, as defined above, or the extract capable of being obtained by the process according to invention as described above.
  • the extract obtainable by the process according to the invention as described above has the same composition as the extract according to the invention as such, as defined above.
  • a subject of the invention is also a composition
  • a composition comprising an extract rich in polysaccharides of flowers, preferably calyxes, of Bombax costatum according to the invention and a water/solvent mixture in a water/solvent ratio (v/v) of between 50 /50 and 0/100, advantageously between 30/70 and 10/90, more advantageously 20/80, said solvent being chosen from glycols, vegetable glycerin and mixtures thereof, preferably from glycols of vegetable origin and glycerin vegetable, and preferably from 1,3-propanediol and vegetable glycerin.
  • the composition comprises from 0.001 to 30% by weight, advantageously 0.001% to 10% by weight, of an extract according to the invention (expressed by weight of dry extract relative to the total weight of the composition) and between 50 % and 99.999% by weight, advantageously between 70% and 99.999% by weight, of a water/solvent mixture, relative to the total weight of the composition, the water/solvent ratio being between 50/50 and 0/100, advantageously between 30/70 and 10/90, more advantageously 20/80, and the solvent being chosen from glycols, vegetable glycerin and mixtures thereof, preferably from glycols of vegetable origin and vegetable glycerin, and preferentially from 1,3-propanediol and vegetable glycerin.
  • the solvent is in an amount effective for a physical and microbiological stabilizing action of the composition according to the invention and in particular of the extract according to the invention.
  • a subject of the invention is also a composition comprising an extract rich in polysaccharides of flowers, preferably calyxes, of Bombax costatum according to the invention, as active principle, and where appropriate a suitable excipient.
  • the extract according to the invention is as defined in the paragraphs above concerning the extract as such and those concerning the extract capable of being obtained by the process according to the invention.
  • composition is advantageously cosmetic, pharmaceutical or dermatological.
  • Said composition is preferably formulated to be administered by external topical route.
  • the composition according to the invention comprises from 0.001 to 10%, typically from 0.01 to 5%, by weight of extract according to the invention, the weight of the extract being expressed as dry extract, relative to the weight composition total.
  • composition according to the invention may also comprise one or more other active principles.
  • composition according to the invention can be formulated in the form of various preparations suitable for topical administration and include in particular creams, emulsions, milks, ointments, lotions, oils, aqueous or hydro-alcoholic or glycolic solutions, powders, patches, sprays, shampoos, varnishes or any other product for external application.
  • the composition according to the invention may also comprise at least one cosmetically, pharmaceutically or dermatologically acceptable excipient.
  • composition according to the present invention may also comprise at least one cosmetically, pharmaceutically or dermatologically known adjuvant to those skilled in the art, in particular chosen from surfactants, thickeners, preservatives, perfumes, dyes, filters chemicals or minerals, moisturizing agents, and thermal waters.
  • a person skilled in the art knows how to adapt the formulation of the composition according to the invention by using his general knowledge.
  • the optimal dosages and galenic forms of the compositions according to the invention can be determined according to the criteria generally taken into account in the establishment of a pharmacological, dermatological or cosmetic treatment adapted to a patient or to an animal, such as for example the age or body weight of the patient or animal, the severity of his general condition, tolerance to treatment, side effects observed, type of skin.
  • a subject of the invention is also an extract according to the invention or a composition according to the invention for its use for preventing and/or treating disorders or pathologies of the skin and/or mucous membranes (gums, periodontium, genital mucous membranes) and / or appendages (hair and nails) immature(s), normal(s) or mature/aged(s), in particular inflammatory reactions, oxidation reactions, disorders linked to radical attacks linked or not to pollution, disorders or pathologies linked to microbial attacks, barrier or homeostasis disorders, aging, in particular chronological and/or actinic aging, disorders or pathologies linked to mechanical and/or thermal attacks on the skin and/or mucous membranes and/or appendages; more advantageously inflammatory or irritative reactions or pathologies or disorders of the barrier or homeostasis of the skin, appendages and/or mucous membranes (gums, periodontium, genital mucosa) immature(s), normal(s) or mature/
  • a subject of the invention is also an extract according to the invention or a composition according to the invention for its use for preventing and/or treating imbalances and/or disorders linked to the imbalance of the microbiota of the skin and/or mucous membranes ( gums, periodontium, genital mucosa) and/or appendages and/or their appendages, immature(s), normal(s) or mature/aged.
  • the extract according to the invention has a protective activity of the skin and / or mucous membranes (gums, periodontium, genital mucous membranes) and / or appendages and / or their annexes, immature (s), normal (s) or mature(s)/aged(s), against mechanical, microbial, thermal and radical attacks.
  • the extract according to the invention acts for the defense of the microbiota and therefore makes it possible to fight against the microbiota imbalance.
  • the extract according to the invention makes it possible to stimulate the immune defenses of the skin and the cutaneous antioxidant system.
  • a subject of the invention is also the use of an extract according to the invention or of a composition according to the invention for the manufacture of a cosmetic, pharmaceutical or dermatological composition for preventing and/or treating disorders or pathologies of skin and/or mucous membranes (gums, periodontium, genital mucosa) and/or appendages (hair and nails) immature(s), normal(s) or mature/aged(s), in particular inflammatory reactions , oxidation reactions, disorders linked to radical attacks whether or not linked to pollution, disorders or pathologies linked to microbial attacks, barrier or homeostasis disorders, ageing, in particular chronological aging and/or or actinic, disorders or pathologies linked to mechanical and/or thermal attacks on the skin and/or mucous membranes and/or appendages; more advantageously inflammatory or irritative reactions or pathologies or disorders of the barrier or homeostasis of the skin, appendages and/or mucous membranes (gums, periodontium, genital mucous membrane
  • the invention also relates to the use of an extract according to the invention or a composition according to the invention for the manufacture of a pharmaceutical, cosmetic or dermatological composition for preventing and / or treating imbalances and / or disorders related to the imbalance of the microbiota of the skin and/or mucous membranes (gums, periodontium, genital mucous membranes) and/or appendages and/or their appendages, immature(s), normal(s) or mature/aged(s) ).
  • the invention further relates to a method for preventing and / or treating disorders or pathologies of the skin and / or mucous membranes (gums, periodontium, genital mucous membranes) and / or appendages (hair and nails) immature (s) , normal(s) or mature(s)/aged(s), in particular inflammatory reactions, oxidation reactions, disorders linked to radical attacks linked or not to pollution, disorders or pathologies linked to microbial attacks , barrier or homeostasis disorders, aging, in particular chronological and/or actinic aging, disorders or pathologies linked to mechanical and/or thermal attacks on the skin and/or mucous membranes and/or appendages; more advantageously inflammatory or irritative reactions or pathologies or disorders of the barrier or homeostasis of the skin, appendages (hair and nails) and/or mucous membranes (gums, periodontium, genital mucous membranes) immature(s), normal (s) or mature(s
  • the invention also relates to a method for preventing and/or treating imbalances and/or disorders related to the imbalance of the microbiota of the skin and/or mucous membranes (gums, periodontium, genital mucous membranes) and/or appendages and/or or their annexes, immature(s), normal(s) or mature(s)/aged(s), comprising the administration, in particular the topical administration, of an effective amount of an extract according to the invention or of a composition according to the invention, to a subject in need thereof.
  • composition or the extract according to the invention is intended for the prevention and/or treatment of inflammatory or irritative reactions or pathologies or disorders of the barrier or of the homeostasis of the skin, skin appendages (hair and nails) and/or mucous membranes (gums, periodontium, genital mucosa) immature(s), normal(s) or mature(s)/aged(s) .
  • the inflammatory, irritative reactions, disorders or pathologies or disorders of the barrier or homeostasis of the skin are: acne, rosacea or erythrocouperosis, vascular disorders, in particular redness and rosacea, dermatitis diaper, atopic dermatitis, eczema, contact dermatitis, irritative dermatitis, allergic dermatitis, seborrhoeic dermatitis (cradle cap), sensitive skin, reactive skin, dry skin (xerosis), skin dehydrated, skin with redness, skin erythema, aged or photo-aged skin, photosensitized skin, pigmented skin (melasma, post-inflammatory pigmentation...), skin with stretch marks, sunburn, irritation by chemical, physical (for example tension stress for pregnant women), bacteriological, fungal agents, skin aging, in particular photoaging and disorders linked to radical attacks linked to chemical pollution mic or atmospheric, and/or related to exposure to UV or IR.
  • the inflammatory, irritative reactions, disorders or pathologies or disorders of the barrier or homeostasis of the mucous membranes are gingivitis (sensitive gums of newborns, hygiene problems, due to smoking or other), and irritation of the external or internal male or female genital spheres.
  • the inflammatory, irritative reactions, disorders or pathologies or disorders of the barrier or of the homeostasis of the appendages are brittle nails, fragile nails, weakened hair, brittle hair, dry hair.
  • the reactions, disorders or pathologies linked to the imbalance of the cutaneous microbiota are atopic dermatitis, eczema, the development of bad underarm odors, the weakening of the skin barrier, acne, psoriasis, and hidradenitis suppurativa.
  • the reactions, disorders or pathologies linked to the imbalance of the microbiota of the appendages are folliculitis, cradle cap, dandruff, itching of the scalp.
  • the reactions, disorders or pathologies linked to the imbalance of the microbiota of the mucous membranes are itching, irritation, candidiasis, and bacterial vaginosis.
  • a subject of the invention is also the cosmetic use of an extract according to the invention or of a composition according to the invention, advantageously on healthy subjects, in the treatment and/or prevention of dehydrated skin; the skin with redness; aged or photo-aged skin; photosensitized skin; skin ageing, in particular photoaging; and disorders linked to radical attacks linked to chemical or atmospheric pollution, and/or linked to exposure to UV or IR.
  • a subject of the invention is also the cosmetic use of an extract according to the invention or of a composition according to the invention for caring for skin appendages, advantageously on healthy subjects, in particular for the treatment and/or prevention of brittle nails; brittle nails; weakened hair; brittle hair; and dry hair.
  • the invention also relates to a method for cosmetic care of the skin and/or appendages and/or mucous membranes, with a view to improving their condition and/or their appearance, advantageously on healthy subjects, consisting in administering a composition or a extract according to the present invention.
  • the invention relates to a method for the cosmetic care of the skin and/or appendages, with a view to preventing the alterations of the barrier and its dehydration, advantageously on healthy subjects, consisting in applying to the skin and/ or appendages a composition or an extract according to the present invention.
  • the invention relates to a cosmetic care process for the skin and/or appendages, advantageously on healthy subjects, for preventing and/or treating alterations in the skin barrier; dehydrated skin; the skin with redness; aged skin or aged photo; photosensitized skin; skin ageing, in particular photoaging; disorders linked to mechanical or thermal aggression of the skin and disorders linked to free-radical attacks linked to chemical or atmospheric pollution, and/or linked to exposure to UV or IR rays, consisting in administering a composition or one of extracts according to the present invention.
  • FIGURES Figure 1 represents the growth curves of C. acnes and M.furfur (cf. Example 2-V-b.).
  • Figure 2 represents the effect of the active ingredient BCP on the bacterial growth of different strains in co-culture as a function of time (cf. Example 2-V-b.).
  • Figure 3 represents the analysis of the morphology of the RHEs after Hematoxylin/Eosin staining (cf. Example 2-VI-b.).
  • FIG. 4a and FIG. 4b represent the growth curves of the lactobacillus strains (cf. Example 2-VII-b.).
  • Figure 5 represents the analysis of the formation of biofilm by different strains of the cutaneous microbiota in the presence of the active ingredient BCP (see Example 2-IX).
  • Example 1 Preparation of a solution of polysaccharides from calyxes of Bombax costatum
  • Bombax costatum chalices are ground, then suspended with stirring in water at a proportion of 2% w/w chalices/water;
  • BCP extract The Bombax costatum polysaccharide extract according to Example 1 (called BCP extract) at 0.05% dry matter was added to the culture medium of normal human dermal fibroblasts (NHDLs) or of reconstituted melanized human epidermis.
  • the BCP extract increases the gene expression of 2 enzymes involved in the synthesis or remodeling of lipids within the stratum corneum:
  • the active ingredient BCP makes it possible to reinforce the barrier function of the epidermis and its hydration.
  • the active BCP increases the expression of syndecan-1 (SDC1).
  • SDC1 syndecan-1
  • Keratin 19 encoded by the KRT19 gene is an epithelial marker considered as a marker of epidermal stem cells.
  • the BCP extract By stimulating the expression of KRT19, the BCP extract has a protective effect on stem cells.
  • the BCP extract causes a decrease in the expression of the MITF gene.
  • the BCP extract exhibits melanogenesis inhibitory activity.
  • Table 2 below presents the most significant results of the BCP extract on the expression of genes in fibroblasts.
  • the BCP extract induces the expression of several enzymes involved in antioxidant defence: superoxide dismutases, in particular superoxide dismutase 1 (Cu/ZnSOD) encoded by the SOD1 gene and superoxide dismutase 2 (MnSOD) encoded by the SOD2.
  • superoxide dismutases in particular superoxide dismutase 1 (Cu/ZnSOD) encoded by the SOD1 gene and superoxide dismutase 2 (MnSOD) encoded by the SOD2.
  • the active BCP also induces the expression of one of the 2 isoforms of metallothionein 1 (MT1G).
  • the active BCP also induces the TXNRD1 gene encoding isoform 1 of thioredoxin reductase.
  • the joint induction of these genes coding for proteins possessing an antioxidant and/or detoxifying activity confers protection against UV rays and heavy metals resulting from urban pollution, for example.
  • the main function of fibroblasts present in the dermis is to produce, degrade, and therefore regulate the components of the extracellular matrix (ECM) with which they interact.
  • ECM extracellular matrix
  • the ECM is a complex structure formed by a network of collagen fibers, elastin fibers and structural glycoproteins.
  • ECM proteins regulated by the active ingredient BCP we find elastin (ELN) but also fibrillin-1 and -2 encoded respectively by the FBN1 and FBN2 genes.
  • the active BCP In addition to the induction of the ELN and FBN1 genes, the active BCP also induces FBN2, also constituting the micro fibrils.
  • the BCP active ingredient also acts on the collagen fibers since it increases the expression of the alpha 1 subunit of collagen 3 (COL3A1).
  • lamin B1 (LMNB1)
  • LMNB1 lamin B1
  • senescence related to age or associated with skin pathologies is accompanied by a loss of expression, at the protein and mRNA level, of lamin B1 (Dreesen, O. et al., 2013. The contrasting roles of lamin B1 in cellular aging and human disease Nucleus, 4(4), pp. 283-290).
  • LMNB1 LMNB1 within dermal fibroblasts testifies to an effect of the BCP active ingredient reducing senescence which may be associated with age or skin pathologies, and on the other hand s is beneficial for maintaining core structure and integrity.
  • the BCP extract induces a decrease in the expression of SESN2.
  • SESN2 in particular is involved in the UV response of skin cells. This goes in the direction of a greater activity of the mTORCl complex which goes hand in hand with a decrease in the autophagic activity of the cells and thus a regulatory effect of the mitophagic activity.
  • integrins are bound, via adhesion proteins, to intracellular actin filaments.
  • cytoplasmic adhesion proteins we find in particular talin-1 encoded by the TLN1 gene overexpressed by the active BCP. It constitutes the initial link between integrins and the actin cytoskeleton.
  • the binding of talin to integrins regulates their affinities for the ECM, whereas the binding of talin to actin constitutes the first link to the contractile machinery of cells.
  • Prostaglandin-endoperoxide synthases including cyclooxygenase-2 COX2 or PTGS2, catalyze the biosynthesis of prostaglandins (PG) from arachidonic acid in order to induce the inflammatory process via the secretion of cytokines and cutaneous vasodilation.
  • PG prostaglandins
  • the decrease in COX2 expression test ifies to the ability of the active BCP to reduce a possible inflammatory phenomenon that can be induced by different stimuli such as pathogens, UVs, ionizing radiation, etc.
  • ILla interleukin la
  • PGE2 prostaglandin-E2
  • ILip Interleukin 1b
  • TNFa Tumor Necrosis Factor a
  • IL6 Interleukin ⁇
  • IL8 Interleukin 8
  • Table 7 Dosage of TNF-alpha produced by KHNs under the effect of PMA stress $$$p ⁇ 0.001 vs. Control; *p ⁇ 0.05 ***p ⁇ 0.001 vs PMA One-way ANOVA followed by Tukey's test
  • Table 8 Dosage of PGE2 produced by KHNs under the effect of PMA stress $$$p ⁇ 0.001 vs Control; **p ⁇ 0.01 ***p ⁇ 0.001 vs PMA; ns Not Significant One-way ANOVA followed by Tukey's test
  • BCP extract Polysaccharides extract of Bombax costatum according to example 1
  • a photo was taken at the start of treatment and after 5 hours of incubation in order to measure the rate of progression of the HCNs within the lesion. The percentage of coverage was evaluated under the different conditions by image analysis.
  • BCP extract Polysaccharides extract of Bombax costatum according to example 1
  • AMPs anti-microbial peptides
  • TLR2 epidermal keratinocytes
  • the BCP extract significantly stimulated the gene and protein expression of defensins and TLR2; thus demonstrating anti-microbial activity and activation of immune defences.
  • RHE Human Reconstructed Epidermis
  • the counting of bacteria was carried out by counting the colonies after inoculation on specific agar of the ground RHE. The result is expressed in CFU/RHE (colony forming unit).
  • the BCP extract induced a marked inhibition of the adhesion of S. aureus to RHE. At 2%, the BCP extract also inhibited the adhesion of C. acnes. (See table 12)
  • the BCP extract significantly inhibited the adhesion of C. xerosis to the surface of explants (cf. table 13).
  • the BCP extract promotes a rebalancing of the skin microbiota by limiting the adhesion of pathogenic bacteria while preserving the adhesion of commensal bacteria.
  • BCP extract polysaccharide extract of Bombax costatum according to example 1
  • Staphylococcus epidermidis ATCC 12228
  • Cutibacterium acnes ATCC 11827
  • Staphylococcus hominis ATCC 27844. - Determination of the minimum inhibitory concentration (MIC) and determination of the "activator" potential of bacterial growth:
  • the BCP extract was diluted in microplates at 0.25%; 0.5%; 1%; 2%; 4% and 8%, in the minimal culture medium specific to each strain.
  • the controls were prepared in a similar way to T sample: - A positive control for growth inhibition: Phenonip® 5% in the diluted medium,
  • the strains were added to the different conditions before incubation for 48 hours.
  • the BCP extract showed a nourishing effect against S. epidermidis, S. hominis and C. acnes strains and tended to inhibit the growth of S. aureus (bactericidal effect) (see figure 2).
  • Staphylococcus aureus The bacterium Staphylococcus aureus (S. aureus) is frequently detected in patients with atopic dermatitis.
  • the BCP extract according to Example 1 at 1% was applied as a 24-hour pre-treatment to the surface of reconstructed human epidermis (RHE).
  • RHEs were then treated topically by depositing the secretum (culture medium) of Staphylococcus aureus (ATCC 33592). After an additional 24 hours of incubation, a morphological analysis of the tissues was carried out after Hematoxylin/Eosin staining, as well as the analysis of the expression of barrier function markers by immunofluorescence. The level of expression of the proteins of interest was evaluated by semi-quantification using Image J software. b) Results
  • the secretum of S. aureus induced a moderate alteration in the morphology of the RHE: disorganization of the structure of the epidermis (basal layer), fewer grains of keratohyaline at the level of the granular layer.
  • the pre-treatment with the BCP extract preserved the morphology of the epidermis which are better organized, thicker and with a more marked production of keratohyaline grains.
  • barrier function markers As demonstrated by the results in Table 14, S. aureus secretum significantly reduced the level of expression of the barrier function markers studied: comeodesmosine, desmoglein-1 and filaggrin. This model is therefore representative of the negative impact of S. aureus on the barrier function, in particular in the pathophysiology of atopic dermatitis.
  • the BCP extract made it possible to counterbalance this decrease in expression.
  • Table 14 Expression of barrier markers in RHE $p ⁇ 0.05; $$ p ⁇ 0.01 vs Control; *p ⁇ 0.05;**p ⁇ 0.01 vs secretum - Unpaired t test
  • the BCP extract could therefore protect the skin from attack by S. aureus.
  • the prebiotic efficacy of the BCP extract according to example 1 was evaluated on 3 strains of Lactobacilli representative of the vaginal tract; in addition, the BCP extract was studied in a reconstructed model of vaginal epithelium colonized by strains of lactobacilli representative of the resident microflora.
  • L. gasseri ATCC 33323
  • LA-14 L. acidophilus
  • L. rhamnosus ATCC 53103
  • BCP extract Bombas costatum polysaccharide extract according to example 1
  • the bacterial growth was evaluated by spectrophotometric measurement of the OD at 600 nm (which gives an indication of the rate of bacterial replication), as well as the bacterial viability expressed in CFU/ml (to quantify the number viable residual bacteria).
  • the influence on bacterial metabolism was evaluated by measuring the production of lactic acid in the culture supernatants after 24 hours of incubation.
  • the BCP extract had a similar or even greater effect than the positive control (glucose) on the viability of lactobacilli, confirming its prebiotic effect.
  • BCP extract induced a prebiotic effect on L. acidophilus.
  • Lactic acid a product of the primary metabolism of lactobacilli, was quantified in L. Acidophilus culture media (see Table 16).
  • the BCP extract induced an increase in lactic acid production by L. acidophilus.
  • HVE colonized vaginal epithelium
  • Staphylococcus epidermidis ATCC 122278 and Corynebacterium striatum (ATCC 6940) strains were used.
  • Each bacterial strain was inoculated into a reconstituted sweat solution in the presence of the 0.1% BCP extract; 0.6% or 2% or 0.1% chlorhexidine digluconate (positive control). After 6h and 24h of incubation:
  • the bacterial viability was evaluated by bacterial count expressed in CFU/ml.
  • a sniff test was carried out in order to determine the olfactory signature qualitatively and semi-quantitatively (intensity of the odor): immediately after opening the vial, the odor was evaluated and scored by a trained operator: 1. Absent (comparable to positive control chlorhexidine 0.1%)
  • the BCP extract inhibited the odor produced by S. epidermidis and C. striatum compared to the negative control, without altering the viability of these bacteria (cf. table 19).
  • a biofilm is defined as the assembly of microbial cells associated with a living organism or a tissue and "coated” in a polysaccharide matrix.
  • Biofilm is one of the most important virulence factors in infectious diseases, it confers resistance to antibiotics, protection against defenses of the host, it increases the virulence of pathogenic bacteria by promoting their communication system (Quorum Sensing).
  • biofilms have been described in different pathologies or disorders: acne, rosacea, atopic dermatitis. Biofilms are also likely to disrupt healing mechanisms.
  • Biofilms Bacteria that associate in biofilm have an innate resistance to antibiotics, disinfectants and host defense systems; biofilms thus promote the persistence of pathogenic bacteria and their recalcitrance to treatment.
  • the involvement of the Staphylococcus aureus biofilm has been particularly described in the context of the pathophysiology of atopic dermatitis. Indeed, probably due to the alteration of the surface of the skin which allows it to adhere, 5. aureus is more easily found in the form of a biofilm in atopic skin; this state of biofilm promotes its resistance to treatment and increases its virulence, which results in the induction of chronic inflammation and pruritus, phenomena that contribute to the vicious circle of the pathogenesis of atopic dermatitis.
  • Staphylococcus epidermidis MFP04 healthy human skin strain (LMSM strain) characterized by metabolic analysis, AR 16S and genomic sequencing. It is a strain rather described as commensal.
  • Staphylococcus aureus MFP03 healthy human skin strain (FMSM strain) characterized by metabolic analysis, AR 16S and genomic sequencing. It is a commensal strain, an “opportunistic” pathogen, which can be responsible for certain skin infections and widely described as being involved in the pathophysiology of atopic dermatitis.
  • Corynebacterium xerosis CIP 100653T/ATCC373 strain from international databases. It is a commensal strain, involved in the production of axillary odors.
  • Cutibacterium propionibacterium acnes HL045PA1/HM-516 ribotype 4 (RT4): “acneic” strain characterized by Fitz-Gibbon et al. and obtained from an international database. It is a pathogenic strain, involved in the pathogenesis of acne.
  • Cutibacterium propionibacterium acnes HL110PA3/HM-554 ribotype 6 (RT6): “non-acneic” strain characterized by Fitz-Gibbon et al. and obtained from an international database. It is a commensal strain.
  • RT6 ribotype 6
  • LMSM strain healthy human skin strain characterized by metabolic analysis, 16S RNA and genomic sequencing. It is a commensal strain.
  • the active diluted l / 50 th was added to the medium at the beginning of culture. Bacterial growth was monitored in microplates over 24h, 48h or 72h depending on the strain. Absorbance was measured continuously using a microplate reader/incubator.
  • biofilm of bacterial species was studied in multi-well plates (96) using the crystal violet staining technique after culture in the presence of the active ingredient for 24, 48 or 72 hours depending on the strain.
  • the BCP extract of kapok polysaccharides according to the invention did not significantly modify the kinetics of bacterial growth under the conditions of the test.
  • the study of the production of biofilm by the various bacterial strains demonstrated the following effects of the extract of kapok polysaccharides (Cf figure 5): a significant inhibition of the formation of the biofilm of S. aureus; - an induction of the formation of the biofilm of S. epidermis; an absence of significant modulation of the formation of biofilms of M. luteus, C. xerosis or C. acnes RT6 (non-acne strain); inhibition of the formation of the biofilm of the acne strain C. acnes RT4 (acne strain).
  • the BCP extract of kapok polysaccharides inhibits the biofilm-forming capacity of pathogenic bacterial strains (S. aureus and C. acnes RT6 in particular), while preserving or even promoting the capacity of commensal bacteria to form a biofilm.
EP21755806.3A 2020-07-24 2021-07-26 Bombax costatum blütenextrakt mit hohem polysaccharidgehalt Pending EP4185312A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2007834A FR3112685B1 (fr) 2020-07-24 2020-07-24 Extrait de fleurs de bombax costatum riche en polysaccharides
PCT/FR2021/051394 WO2022018392A1 (fr) 2020-07-24 2021-07-26 Extrait de fleurs de bombax costatum riche en polysaccharides

Publications (1)

Publication Number Publication Date
EP4185312A1 true EP4185312A1 (de) 2023-05-31

Family

ID=73793301

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21755806.3A Pending EP4185312A1 (de) 2020-07-24 2021-07-26 Bombax costatum blütenextrakt mit hohem polysaccharidgehalt

Country Status (7)

Country Link
US (1) US20230277613A1 (de)
EP (1) EP4185312A1 (de)
JP (1) JP2023535449A (de)
KR (1) KR20230043873A (de)
CN (1) CN116322729A (de)
FR (1) FR3112685B1 (de)
WO (1) WO2022018392A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103189046B (zh) * 2010-09-09 2016-09-07 玫琳凯有限公司 包含植物提取物的局部护肤制剂
FR2969495B1 (fr) * 2010-12-22 2013-10-11 Expanscience Lab Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant
KR102243502B1 (ko) * 2014-12-05 2021-04-22 코웨이 주식회사 탈분화 식물 프로토플라스트 내에 활성 물질이 인입된 구조체의 안정화 방법
FR3075642B1 (fr) * 2017-12-22 2021-10-22 Expanscience Lab Extrait de fleurs de kapokier et compositions cosmetiques, pharmaceutiques ou dermatologiques le comprenant

Also Published As

Publication number Publication date
US20230277613A1 (en) 2023-09-07
KR20230043873A (ko) 2023-03-31
WO2022018392A1 (fr) 2022-01-27
FR3112685B1 (fr) 2023-12-22
JP2023535449A (ja) 2023-08-17
CN116322729A (zh) 2023-06-23
FR3112685A1 (fr) 2022-01-28

Similar Documents

Publication Publication Date Title
FR2929511A1 (fr) Nouveau principe actif stimulant la proliferation et/ou l'activite des fibroblastes.
EP2986347B1 (de) Kosmetische verwendungen von lactobacillus pentosus
FR2896154A1 (fr) Composition cosmetique ou dermatologique et son utilisation
EP2869827B1 (de) Verwendung eines myrteextrakts als anti-biofilm-mittel gegen p. acnes
KR102367528B1 (ko) 해조류 추출물을 유효성분으로 포함하는 화장료 조성물
JP2023171950A (ja) 抗老化剤、抗酸化剤、抗炎症剤、及び美白剤、並びに、化粧料
FR3051369B1 (fr) Extraits de faine de hetre, compositions et utilisations
EP0909557B1 (de) Verwendung von Honig zur Verminderung von Mikro-Organismenhaftvermögen
EP4185312A1 (de) Bombax costatum blütenextrakt mit hohem polysaccharidgehalt
EP3134101B1 (de) Verwendung von bougainvillea-pflanzenzellen zum einkapseln von aktiven inhaltsstoffen
EP3620212B1 (de) Fermentiertes veilchenextrakt, herstellungsverfahren eines solchen extrakts und einsatz in der kosmetik
KR20220028612A (ko) 인진쑥 추출물 및 올리브 추출물을 유효성분으로 포함하는 항균, 항산화, 미백 및 항염증용 화장료 조성물
EP3856353A1 (de) Verwendung eines agavenextrakts zur verbesserung der barrierefunktion der haut, kopfhaut und/oder schleimhaut und zur modulation der hautmikrobiota
EP3085418B1 (de) Kosmetische zusammensetzungen, die oligomere der hyaluronsäure und dedifferenzierte, aus bougainvillea extrahierte pflanzliche zellen beinhalten, die ein safranextrakt einkapseln
EP3134100B1 (de) Kosmetische zusammensetzungen zur topischen anwendung mit bougainvillea-pflanzenzellen
WO2022157457A1 (fr) Extrait de parties aeriennes de basilic sacre et compositions cosmetiques, ou dermatologiques le comprenant
FR3098119A1 (fr) Procede d’obtention d’une infusion thermale botanique
FR3127219A1 (fr) Nouveaux peptides et compositions pharmaceutiques et cosmetiques les contenants
FR3132436A1 (fr) Procede d’obtention d’extraits vegetaux comprenant une etape d’autofermentation, compositions comprenant de tels extraits et leurs utilisations cosmetiques
FR3068891A1 (fr) Formulation cosmetique caracterisee en ce qu'elle comprend au moins un sel de glucane carboxymethyle et au moins un polymere galactomannane
FR3100134A1 (fr) PRINCIPE ACTIF COSMETIQUE OBTENU PAR BIOCONVERSION PARLactobacillus arizonensisDE SON SUBSTRAT ORIGINEL, PROCEDE D’OBTENTION, COMPOSITION L’INCLUANT ET UTILISATIONS.
WO2012172200A1 (fr) Composition a base de samanea saman pour la protection de la peau

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)